In AML, where on-target off-tumor effects have been observed in single-target CD33 or CD123 CAR-T cell therapies, CD33-/CD123-bispecific CAR-T therapies have been designed to achieve more precise targeting [52]. Here, CD33 is linked to neoplasm.